Table of Contents
4 relations: Alzheimer's disease, American Medical Association, Amyloid beta, Pfizer.
- Anti-amyloid monoclonal antibodies
- Experimental monoclonal antibodies
Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia.
See Ponezumab and Alzheimer's disease
American Medical Association
The American Medical Association (AMA) is an American professional association and lobbying group of physicians and medical students.
See Ponezumab and American Medical Association
Amyloid beta
Amyloid beta (Aβ or Abeta) denotes peptides of 36–43 amino acids that are the main component of the amyloid plaques found in the brains of people with Alzheimer's disease.
See Ponezumab and Amyloid beta
Pfizer
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City.
See also
Anti-amyloid monoclonal antibodies
- Aducanumab
- Amyloid-related imaging abnormalities
- Anti-amyloid drugs
- Bapineuzumab
- Crenezumab
- Donanemab
- Lecanemab
- Ponezumab
- Remternetug
- Solanezumab
- Trontinemab
Experimental monoclonal antibodies
- Abrilumab
- Actoxumab
- Bamlanivimab
- Bebtelovimab
- Bertilimumab
- Bimagrumab
- Bivatuzumab
- Bococizumab
- Catumaxomab
- Clazakizumab
- Clenoliximab
- Dacetuzumab
- Diridavumab
- Edrecolomab
- Emapalumab
- Eptinezumab
- Exbivirumab
- Felvizumab
- Foravirumab
- Garetosmab
- Gatipotuzumab
- Leronlimab
- Libivirumab
- MEDI0618
- Monalizumab
- Motavizumab
- Otelixizumab
- Pagibaximab
- Panobacumab
- Pascolizumab
- Pemivibart
- Pemtumomab
- Pidilizumab
- Ponezumab
- Priliximab
- Regavirumab
- Regdanvimab
- Relatlimab
- Resigratinib
- TB006
- Talizumab
- Tefibazumab
- Tegoprubart
- Temelimab
- Theralizumab
- Tipifarnib
- Tixagevimab/cilgavimab
- Torcetrapib
- Ziltivekimab